333 filings
Page 5 of 17
8-K
j4lm13ge4jw
23 Jun 22
USPTO Issues Patent Covering Use of XPro™ for Treatment of CNS Diseases
4:00pm
8-K
spa04cb
16 Jun 22
Other Events
4:00pm
8-K
ww4keegoixrmfvf2q 1f
1 Jun 22
Submission of Matters to a Vote of Security Holders
4:00pm
8-K/A
ml9mmo0 bgywgo2
24 May 22
Other Events
7:44am
8-K
8a5quw7d8
23 May 22
Other Events
4:04pm
8-K
4uxbtn
18 May 22
INmune Bio, Inc. to Present at the H.C. Wainwright Global Hybrid Investment Conference on May 24th
4:00pm
8-K
1te51be iccg7gcbt9xd
10 May 22
INmune Bio, Inc. Presents Data Demonstrating XPro™ Promotes Remyelination in Gray Matter at 3rd European Conference on Neuroinflammation
4:00pm
8-K
8ac9uwq3w920li8u f2
6 May 22
INmune Bio, Inc. Announces First Quarter 2022 Results and Provides Business Update
8:00am
8-K
13yg3u3yxj
28 Apr 22
INmune Bio, Inc. to Report First Quarter 2022 Financial Results and Provide a Corporate Update on Thursday, May 5
7:01am
8-K
hsgfizrcj
25 Apr 22
INmune Bio, Inc. to Participate at the B. Riley Neuro & Ophthalmology Conference
4:05pm
8-K
l5cy7ucrgj1 38loq
13 Apr 22
INmune Bio Announces First Patient Dosed in Phase 2 XPro1595 Trial for Treatment of Neuroinflammation as a Cause of Alzheimer’s disease
5:27pm
8-K
c0zini24bjsxu
11 Apr 22
INmune Bio, Inc. to Present Preclinical Data on INB03 at the American Association for Cancer Research (AACR) Annual Meeting 2022
4:00pm
8-K
zf7gzytdk h0cpq
5 Apr 22
INmune Bio, Inc. Highlights INKmune™ Data Featured in NK Cells in Solid Tumors Workshop at Innate Killer Summit
5:33pm
8-K
pxmmhd
31 Mar 22
INmune Bio, Inc. Announces Company’s CSO Dr. Mark Lowdell to Co-Host the “NK Cells in Solid Tumors” Workshop at Innate Killer Summit
4:53pm
8-K
k5re74 w4zp
30 Mar 22
Other Events
8:05am
8-K
w3dryrj20 95
25 Mar 22
INmune Bio, Inc. Spotlights Key Findings in Presentations at AD/PD™ 2022
4:22pm
8-K
isng3xc zk4gcapy
24 Mar 22
Departure of Directors or Certain Officers
4:01pm
8-K
efyrxgcvchvzyct9j
24 Mar 22
Entry into a Material Definitive Agreement
4:00pm